KOSDAQBiotech & Pharma256840

BNC Korea

₩2,165▲ 2.36%2026-11-18 close
Market Cap
₩148.1B
Turnover
₩400M
Volume
170K
Shares out.
68.4M
PER
—
PBR
0.7×
EPS
-₩61
Dividend Yield
3.17%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩70 per share · Prices as of the 2026-11-18 close

01

Report overview

Q3 2026 Turnaround; Durability of Earnings Recovery Is the Test

Operating profit returned to the black in Q3 2026, but the sharp earnings decline in 2025 and a cumulative shareholder net loss of KRW 4.18 billion over the last four quarters remain open issues for BNC Korea.

  1. 1

    Operating profit reached KRW 3.24 billion in Q3 2026, turning around from an operating loss of KRW 1.4 billion in Q3 2025.

  2. 2

    Operating profit fell 84.8% year on year to KRW 1.63 billion in 2025, and the operating margin dropped to 1.7%.

  3. 3

    Revenue rose for three consecutive years from 2023 through 2025, reaching KRW 95.9 billion in 2025.

  4. 4

    Q3 2026 revenue of KRW 29.6 billion rose 33.0% year on year and has grown sequentially for two straight quarters since Q2 2026.

  5. 5

    Overseas sales reached KRW 59.3 billion in 2025, accounting for 61.9% of revenue, according to an analysis of the March 2026 annual report by Cosmetic Shinmun.

02

Business structure

BNC Korea is a company that runs aesthetic and healthcare businesses based on biomaterials. Its key products are aesthetic items such as HA fillers, botulinum toxin and dermo-cosmetics, along with surgical biomaterials such as anti-adhesion products and wound dressings.

According to an analysis by Cosmetic Shinmun of the March 2026 annual report, aesthetic plastic surgery products generated KRW 59.1 billion in 2025, or 62% of revenue. Surgical and procedural products contributed KRW 9.1 billion (9%), medical aesthetic devices KRW 2.6 billion (3%), and cosmetics KRW 1.9 billion (2%).

The reagent and testing equipment category recorded KRW 22.2 billion (23%), the second-largest share after aesthetic plastic surgery products. Third-party product distribution sales were KRW 24.6 billion, or 25.7% of revenue, so the distribution business is also a meaningful part of the mix.

Overseas sales rose 11.7% year on year to KRW 59.3 billion in 2025 from KRW 53.1 billion in 2024. In Q3 2026, the company said sales of its Trauma product line for external trauma solutions rose 52.6% year on year and exports rose 114.9%.

The company has consolidated a subsidiary to expand into medical aesthetic devices and bio distribution. In botulinum toxin, it competes with domestic players including Hugel.

Because overseas sales account for a high share of revenue, whether the core product categories keep growing is the key variable for the business structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.3B-₩1.4B−6.3%
2025Q4₩23.6B-₩2.4B−10.0%
2026Q1₩20.7B-₩1.5B−7.1%
2026Q2₩24.6B-₩400M−1.5%
2026Q3₩29.6B₩3.2B10.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩42.3B-₩10.1B-₩44.7B−23.9%−24.3%22.3%
2023₩81B₩6B₩25.7B7.5%12.3%10.2%
2024₩89.2B₩10.7B₩13.3B12.0%5.8%12.9%
2025₩95.9B₩1.6B₩2.8B1.7%1.2%16.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-disclosed basis, revenue rose from KRW 42.3 billion in 2022 to KRW 81 billion in 2023, a 91.5% increase, then grew to KRW 89.2 billion in 2024 (up 10.2%) and KRW 95.9 billion in 2025 (up 7.5%), marking three consecutive years of growth.

Operating results swung from an operating loss of KRW 10.1 billion in 2022 to operating profit of KRW 6.05 billion in 2023, then rose to KRW 10.7 billion in 2024 (up 77.1%). Operating profit fell 84.8% in 2025 to KRW 1.63 billion, and the operating margin declined from 12.0% to 1.7%.

Shareholder net profit peaked at KRW 25.7 billion in 2023 and then declined two years in a row, to KRW 13.3 billion in 2024 (down 48.2%) and KRW 2.84 billion in 2025 (down 78.7%). Net profit including non-controlling interests was KRW 2.05 billion in 2025, a different figure from shareholder net profit.

According to an analysis by Cosmetic Shinmun, the gross margin fell from 46.8% to 41.1% in 2025, and R&D expenses rose 89.8% to KRW 5.1 billion.

The same analysis said profitability at domestic and overseas subsidiaries worsened, and the domestic subsidiary KBTB, a consolidated subsidiary, posted a net loss of KRW 3.9 billion in 2025.

Quarterly results show operating losses of KRW 2.36 billion in Q4 2025, KRW 1.48 billion in Q1 2026 and KRW 366 million in Q2 2026, before an operating profit of KRW 3.24 billion in Q3 2026.

On November 16, 2026, the company said standalone Q3 operating profit was KRW 4 billion with a 17.6% margin, a preliminary figure. The cumulative shareholder net loss over the last four quarters is KRW 4.18 billion.

05

Industry analysis

BNC Korea's business is split into two pillars: aesthetic products (HA fillers, botulinum toxin, dermo-cosmetics) and surgical biomaterials (anti-adhesion products and wound dressings).

Aesthetic products are highly sensitive to demand for cosmetic procedures, and botulinum toxin and HA fillers are contested by many competitors. Aesthetic plastic surgery products accounted for 62% of 2025 revenue, so the company is heavily exposed to this segment.

Surgical and procedural products fell 19% to KRW 9.1 billion in 2025 from KRW 11.3 billion in 2024, according to Cosmetic Shinmun. In Q3 2026, sales of the Trauma product line rose 52.6% year on year, signaling a recovery signal in biomaterials.

In global CMO, the company signed a long-term contract with KIOMED Pharma of Belgium for prefilled syringe medical devices, building a growth driver separate from its aesthetic business. In bio CMO, the scale gap with large players such as Samsung Biologics is wide.

In botulinum toxin, the company is directly compared with Hugel. Relative to other listed peers, its distinguishing feature is that it combines aesthetic materials, distribution and exports.

06

Outlook

Alongside its Q3 2026 disclosure, the company said it would strengthen its aesthetic and healthcare competitiveness based on revenue growth and margin improvement in its core business, and would pursue global CMO and new drug development as new growth drivers.

It has signed a long-term CMO contract with KIOMED Pharma of Belgium for prefilled syringe medical devices, and completed patent registration in China for a liquid dexibuprofen injection. The company presented the CMO contract as a step that widens its overseas contract manufacturing base.

The company said orders for its Trauma product line have steadily increased in key regions such as Latin America following FDA approval. The consolidation of a subsidiary was presented as a way to expand into medical aesthetic devices and bio distribution.

On the earnings side, sales have grown for two consecutive quarters since Q2 2026, and both operating profit and net profit turned positive in Q3 2026. Because the turnaround appears in a single quarter, whether profits hold in subsequent quarters is the next checkpoint.

R&D expenses rose to KRW 5.1 billion in 2025, so how these costs affect the pace of the earnings recovery also needs monitoring. The 2026 annual report will show the full-year operating margin and the contribution from new businesses.

07

Valuation

PER
—
PBR
0.7×
ROE
-1.8%
EPS
-₩61
BPS
₩3,377
Dividend per share
₩70

On net-asset-based measures, the share price sits at a low level. The price-to-book ratio is below 1x, meaning the stock trades below the book value attributable to shareholders.

That book value is based on total equity of KRW 239.5 billion and shareholder equity of KRW 233.7 billion at the end of 2025, and whether asset value converts into earnings should be judged alongside business profitability.

PER cannot be calculated because the cumulative shareholder net loss over the last four quarters is negative. Shareholder net profit fell to KRW 2.84 billion in 2025 and turned positive in Q3 2026, but a recovery has not yet been confirmed on a full-year basis.

The dividend yield reflects dividends currently paid, so dividend sustainability should be checked against earnings when profits are falling. The debt-to-equity ratio was 16.1% at the end of 2025, lower than 22.3% in 2022, after a move to 12.9% in 2024 and a gradual rise.

Multiples in this period reflect a time when earnings fell sharply, so direct comparison with past valuation levels has limits.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Quarterly turnaround and revenue growth

Operating profit reached KRW 3.24 billion in Q3 2026, turning around from an operating loss of KRW 1.4 billion in Q3 2025. Revenue has grown for two straight quarters since Q2 2026, reaching KRW 29.6 billion in Q3 2026, up 33.0% year on year.

The company's standalone operating margin of 17.6% for Q3, announced on November 16, 2026, is preliminary and was attributed to improved profitability in its core business.

Financial capacity and low leverage

Total equity at the end of 2025 was KRW 239.5 billion, of which KRW 233.7 billion belonged to shareholders. Total liabilities were KRW 38.4 billion, and the debt-to-equity ratio was 16.1%. The ratio rose gradually from 10.2% in 2023 to 12.9% in 2024 and 16.1% in 2025, but remains at a low level. Operating cash flow stayed positive at KRW 7.16 billion in 2025.

Overseas CMO and export expansion

The company signed a long-term CMO contract with KIOMED Pharma of Belgium for prefilled syringe medical devices and completed patent registration in China for a liquid dexibuprofen injection. Overseas sales are growing, so the change in the export share is the next checkpoint. The company said exports of its Trauma product line rose 114.9% in Q3 2026.

09

Bear factors

Sharp earnings decline in 2025

Operating profit fell 84.8% in 2025 to KRW 1.63 billion, and the operating margin dropped to 1.7%. Shareholder net profit fell 78.7% to KRW 2.84 billion. According to Cosmetic Shinmun, the gross margin also declined from 46.8% to 41.1%. Revenue rose, but profit did not follow.

Accumulated quarterly losses

Operating losses continued for four straight quarters from Q3 2025 through Q2 2026. The largest loss came in Q4 2025, with an operating loss of KRW 2.36 billion and a shareholder net loss of KRW 2.37 billion.

The cumulative shareholder net loss over the last four quarters is KRW 4.18 billion, so the single profitable quarter in Q3 2026 has not erased the cumulative deficit.

Subsidiary losses and rising borrowings

The domestic subsidiary KBTB, a consolidated subsidiary, posted a KRW 3.9 billion net loss in 2025, and its loss widened sharply from the prior year. Profitability at domestic and overseas subsidiaries worsened from the previous year.

Total borrowings rose to KRW 26.5 billion in 2025 from KRW 14.6 billion, and the interest coverage ratio fell to 2.59 from 32.02, according to Cosmetic Shinmun.

10

Risk factors

Earnings volatility

Operating profit fell sharply in 2025, and Q1 2026 revenue of KRW 20.7 billion dropped 12.1% from the prior quarter. Whether the Q3 2026 turnaround is a one-off or a sustainable recovery can only be determined from the next quarters' results. The standalone Q3 figures are preliminary company announcements and may differ from the final audited numbers.

Overseas and export dependence and regulation

Overseas sales accounted for 61.9% of revenue in 2025, a high share. The company attributed the growth in exports of its Trauma product line to rising orders from Latin America and other regions following FDA approval.

Medical devices and drugs face different approval systems by country, so regulatory changes in key regions or exchange-rate movements could affect export results.

Execution risk and investment burden in new businesses

The contribution of new businesses, including global CMO, new drug development and the consolidation of a subsidiary, will be visible in the 2026 annual report. R&D expenses rose 89.8% to KRW 5.1 billion in 2025, increasing the investment burden. Drug development tends to show results over a long horizon, which can conflict with near-term earnings.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. The key checks are whether quarterly losses recur as they did in Q4 2025 and whether the full-year operating margin recovers from 1.7% in 2025.

  2. Mid-May 2027

    The Q1 2027 quarterly report. The checks are whether the Q3 2026 profitability continues and whether the long-term CMO contract with KIOMED Pharma starts to show up in revenue.

  3. First half of 2027 (date not set)

    Whether the China patent for the dexibuprofen injection and rising Trauma product orders in Latin America are reflected in the overseas sales share and export growth.

12

Overall view

BNC Korea's revenue grew for three consecutive years from 2023 through 2025, centered on its biomaterial-based aesthetic business, and operating profit turned positive in Q3 2026. However, operating profit fell 84.8% in 2025 to KRW 1.63 billion, and the operating margin declined to 1.7%.

The cumulative shareholder net loss over the last four quarters is KRW 4.18 billion, and the turnaround has so far appeared in a single quarter. Bullish factors include quarterly revenue growth, the long-term CMO contract with KIOMED Pharma, and financial capacity with a debt-to-equity ratio of 16.1%.

Bearish factors include the lower gross margin in 2025, the net loss at the subsidiary KBTB, and rising total borrowings. The share price sits below 1x price-to-book, but PER cannot be calculated, which limits earnings-based comparisons. The next checkpoints are the operating margin in the 2026 annual report and quarterly results in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. kr.investing.com
  2. newspim.com
  3. specialtimes.co.kr
  4. rapportian.com
  5. newstap.co.kr
  6. press9.kr
  7. beautynury.com
  8. m.yakup.com
  9. getnews.co.kr
  10. beautynury.com
  11. newstown.co.kr
  12. ebn.co.kr
  13. pharmnews.com
  14. digitaltoday.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis